World-leading companies such as QUINTA-ANALYTICA are embracing new technologies critical to revolutionizing research, attracting patients for trials, and reducing the speed of delivering results.
Adopting cutting-edge technology is playing a vital role now more than ever in the digital revolution of the pharmaceutical industry, with any advancement that may offer improvement quickly becoming a big focus.
World-leading A-Z service companies such as QUINTA-ANALYTICA are constantly adopting more tech and embracing new technologies that are proving critical to revolutionizing research, attracting patients for trials, and reducing the speed of delivering results.
Technologies like Artificial Intelligence (AI), Machine Learning (ML), and digital apps, are allowing pharmaceutical companies to not only improve their access to vital medical and patient information but improve their accuracy and capability.
With AI already being used in the healthcare industry while conducting repetitive tasks such as data entry, lab test analyses, and data management to identify errors or inefficiencies, and ML being used in disease identification and diagnosis, clinical trial research, and new drug invention, it’s clear that tech is ingrained in an irreversible way.
Further used to improve operational, regulatory, and financial performance, the answer is certain that in modern companies like Quinta, tech undoubtedly helps pharma.
18 July 2023
Challenges of a large-scale study of breast cancer
Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.
29 June 2023
EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.
After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.
22 June 2023
Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies
EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency